GENISE BINNS: Open Payments
NPI 1154989408 · VIRGINIA BEACH, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,241 in 109 payments from 15 companies in 2025. Trend: 2023 $2,565 · 2024 $5,109 · 2025 $2,241
Food & beverage: $2,237Education: $4
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $564 |
| E.R. Squibb & Sons, L.L.C. | 19 | $349 |
| Vanda Pharmaceuticals Inc. | 11 | $292 |
| Neurocrine BioSciences, Inc. | 13 | $242 |
| Alkermes, Inc. | 10 | $178 |
| Otsuka America Pharmaceutical, Inc. | 8 | $161 |
| Axsome Therapeutics, Inc. | 5 | $103 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Supernus Pharmaceuticals, Inc. | 3 | $56 |
Products named: VRAYLAR, COBENFY, FANAPT, INGREZZA, ARISTADA, REXULTI, Auvelity, CAPLYTA.
Industry payments across VA — which companies pay providers there.
